Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease

Biochemical Pharmacology

Volumn 88, Issue 4, 2014, Pages 508-516

  Overk, Cassia R ^a   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Lewy body disease; Synapse; Synuclein; Tau

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; GLUTAMATE RECEPTOR; OLIGOMER; TAU PROTEIN;

ALZHEIMER DISEASE; DIFFUSE LEWY BODY DISEASE; HUMAN; MITOCHONDRION; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYNAPSE VESICLE; SYNAPTIC TRANSMISSION;

ALZHEIMER'S DISEASE; LEWY BODY DISEASE; SYNAPSE; SYNUCLEIN; TAU;

ALZHEIMER DISEASE; HUMANS; LEWY BODY DISEASE; SYNAPSES; SYNUCLEINS;

EID: 84897437047     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.01.015     Document Type: Review

References (184)

1. C.R. Jack Jr., M.S. Albert, D.S. Knopman, G.M. McKhann, R.A. Sperling, and M.C. Carrillo et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 257 262
2. B.T. Hyman, C.H. Phelps, T.G. Beach, E.H. Bigio, N.J. Cairns, and M.C. Carrillo et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease Alzheimers Dement 8 2012 1 13
3. D. Galasko, and T.E. Golde Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems Alzheimers Res Ther 5 2013 10
4. K.A. Johnson, S. Minoshima, N.I. Bohnen, K.J. Donohoe, N.L. Foster, and P. Herscovitch et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association Alzheimers Dement 9 2013 e1 e16
5. J.H. Kang, M. Korecka, J.B. Toledo, J.Q. Trojanowski, L.M. Shaw, and Clinical Utility Analytical challenges in measurement of cerebrospinal fluid amyloid-beta1-42 and tau proteins as Alzheimer disease biomarkers Clin Chem 2013 903 916
6. K. Bettens, K. Sleegers, and C. Van Broeckhoven Genetic insights in Alzheimer's disease Lancet Neurol 12 2013 92 104
7. R.E. Tanzi The genetics of Alzheimer disease Cold Spring Harb Perspect Med 2 2012 a006596
8. C.L. Masters, and D.J. Selkoe Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease Cold Spring Harb Perspect Med 2 2012 a006262
9. M. Stefani Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer's disease and other diseases with amyloid deposits Prog Neurobiol 99 2012 226 245
10. C.J. Sarell, P.G. Stockley, and S.E. Radford Assessing the causes and consequences of co-polymerization in amyloid formation Prion 7 2013 359 368
11. A.S. Chesser, S.M. Pritchard, and G.V. Johnson Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease Front Neurol 4 2013 122
12. A.M. Cardenas, A.O. Ardiles, N. Barraza, X. Baez-Matus, and P. Caviedes Role of tau protein in neuronal damage in Alzheimer's disease and Down syndrome Arch Med Res 43 2012 645 654
13. I.G. McKeith Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop J Alzheimers Dis 9 2006 417 423 (Pubitemid 44253336)
14. M.J. Farrer Genetics of Parkinson disease: paradigm shifts and future prospects Nat Rev Genet 7 2006 306 318
15. T.L. Edwards, W.K. Scott, C. Almonte, A. Burt, E.H. Powell, and G.W. Beecham et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease Ann Hum Genet 74 2010 97 109
16. M. Ozansoy, and A.N. Basak The central theme of Parkinson's disease: alpha-synuclein Mol Neurobiol 47 2013 460 465
17. J. Hardy Genetic analysis of pathways to Parkinson disease Neuron 68 2010 201 206
18. Alzheimer's Association Alzheimer's disease facts and figures Alzheimer's Dement 9 2013 1 71
19. C.R. Jack Jr., H.J. Wiste, S.D. Weigand, D.S. Knopman, V. Lowe, and P. Vemuri et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity Neurology 81 2013 1732 1740
20. B.T. Hyman, and J.Q. Trojanowski Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease J Neuropathol Exp Neurol 56 1997 1095 1097
21. D.R. Thal, U. Rub, M. Orantes, and H. Braak Phases of A beta-deposition in the human brain and its relevance for the development of AD Neurology 58 2002 1791 1800 (Pubitemid 34663580)
22. H. Braak, and E. Braak Neuropathological staging of Alzheimer-related changes Acta Neuropathol 82 1991 239 259
23. S.S. Mirra, A. Heyman, D. McKeel, S.M. Sumi, B.J. Crain, and L.M. Brownlee et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease Neurology 41 1991 479 486
24. R.L. Hamilton Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry Brain Pathol 10 2000 378 384 (Pubitemid 30431290)
25. G.M. Halliday, J.L. Holton, T. Revesz, and D.W. Dickson Neuropathology underlying clinical variability in patients with synucleinopathies Acta Neuropathol 122 2011 187 204
26. L. Hansen, E. Masliah, and R. Terry A neuropathologic subset of Alzheimer's disease with concomitant Lewy body disease and spongiform change Acta Neuropathol 78 1989 194 201 (Pubitemid 19160924)
27. W. Wei, L.N. Nguyen, H.W. Kessels, H. Hagiwara, S. Sisodia, and R. Malinow Amyloid beta from axons and dendrites reduces local spine number and plasticity Nat Neurosci 13 2010 190 196
28. A. Iwai, E. Masliah, M. Yoshimoto, R. De Silva, N. Ge, and A. Kittel et al. The precursor protein of non-Aβ component of Alzheimer's disease amyloid (NACP) is a presynaptic protein of the central nervous system Neuron 14 1994 467 475
29. P. Hollingworth, D. Harold, R. Sims, A. Gerrish, J.C. Lambert, and M.M. Carrasquillo et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease Nat Genet 43 2011 429 435
30. A.C. Naj, G. Jun, G.W. Beecham, L.S. Wang, B.N. Vardarajan, and J. Buros et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease Nat Genet 43 2011 436 441
31. R. Guerreiro, A. Wojtas, J. Bras, M. Carrasquillo, E. Rogaeva, and E. Majounie et al. TREM2 variants in Alzheimer's disease N Engl J Med 368 2013 117 127
32. V. Swarup, and D.H. Geschwind Alzheimer's disease: from big data to mechanism Nature 500 2013 34 35
33. N. Ertekin-Taner Alzheimer disease: the quest for Alzheimer disease genes - focus on CSF tau Nat Rev Neurol 9 2013 368 370
34. E. Pham, L. Crews, K. Ubhi, L. Hansen, A. Adame, and A. Cartier et al. Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins FEBS J 277 2010 3051 3067
35. S.W. Scheff, D.A. Price, F.A. Schmitt, K.N. Roberts, M.D. Ikonomovic, and E.J. Mufson Synapse stability in the precuneus early in the progression of Alzheimer's disease J Alzheimers Dis 35 2013 599 609
36. E. Masliah, L. Hansen, R. DeTeresa, and R. Terry Confocal laser imaging of synapse-plaque relationships in Alzheimer disease J Neuropathol Exp Neurol 49 1990 335
37. L. Alonso-Nanclares, P. Merino-Serrais, S. Gonzalez, and J. DeFelipe Synaptic changes in the dentate gyrus of APP/PS1 transgenic mice revealed by electron microscopy J Neuropathol Exp Neurol 72 2013 386 395
38. L. Mucke, E. Masliah, G.Q. Yu, M. Mallory, E.M. Rockenstein, and G. Tatsuno et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation J Neurosci 20 2000 4050 4058 (Pubitemid 30365675)
39. D.B. Freir, R. Fedriani, D. Scully, I.M. Smith, D.J. Selkoe, and D.M. Walsh et al. Abeta oligomers inhibit synapse remodelling necessary for memory consolidation Neurobiol Aging 32 2011 2211 2218
40. P.M. Canas, A.P. Simoes, R.J. Rodrigues, and R.A. Cunha Predominant loss of glutamatergic terminal markers in a beta-amyloid peptide model of Alzheimer's disease Neuropharmacology 76 Pt A 2014 51 56
41. S. Mitew, M.T. Kirkcaldie, T.C. Dickson, and J.C. Vickers Altered synapses and gliotransmission in Alzheimer's disease and AD model mice Neurobiol Aging 34 2013 2341 2351
42. E.J. Mufson, L. Binder, S.E. Counts, S.T. DeKosky, L. de Toledo-Morrell, and S.D. Ginsberg et al. Mild cognitive impairment: pathology and mechanisms Acta Neuropathol 123 2012 13 30
43. S.W. Scheff, D.A. Price, F.A. Schmitt, S.T. DeKosky, and E.J. Mufson Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment Neurology 68 2007 1501 1508 (Pubitemid 46685921)
44. N.C. Berchtold, P.D. Coleman, D.H. Cribbs, J. Rogers, D.L. Gillen, and C.W. Cotman Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer's disease Neurobiol Aging 34 2013 1653 1661
45. R.Y. Chang, A.S. Nouwens, P.R. Dodd, and N. Etheridge The synaptic proteome in Alzheimer's disease Alzheimers Dement 9 2013 499 511
46. R.D. Terry, E. Masliah, D.P. Salmon, N. Butters, R. DeTeresa, and R. Hill et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment Ann Neurol 30 1991 572 580
47. S. DeKosky, and S. Scheff Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity Ann Neurol 27 1990 457 464 (Pubitemid 20149963)
48. S.T. DeKosky, S.W. Scheff, and S.D. Styren Structural correlates of cognition in dementia: quantification and assessment of synapse change Neurodegeneration 5 1996 417 421 (Pubitemid 27077903)
49. S.W. Scheff, S.T. DeKosky, and D.A. Price Quantitative assessment of cortical synaptic density in Alzheimer's disease Neurobiol Aging 11 1990 29 37 (Pubitemid 20097857)
50. S. Scheff, D. Sparks, and D. Price Quantitative assessment of synaptic density in the entorhinal cortex in Alzheimer's disease FASEB J 34 1993 356 361 (Pubitemid 23259604)
51. E. Masliah, and R. Terry The role of synaptic pathology in the mechanisms of dementia in Alzheimer's disease Clin Neurosci 1 1994 192 198
52. M. Ingelsson, H. Fukumoto, K.L. Newell, J.H. Growdon, E.T. Hedley-Whyte, and M.P. Frosch et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain Neurology 62 2004 925 931 (Pubitemid 38435780)
53. S. Scheff, S. DeKosky, and D. Price Quantitative assessment of cortical synaptic density in Alzheimer's disease Neurobiol Aging 11 1990 29 37 (Pubitemid 20097857)
54. S. Scheff, and D. Price Synapse loss in the temporal lobe in Alzheimer's disease Ann Neurol 33 1993 190 199 (Pubitemid 23039928)
55. D. Krstic, and I. Knuesel Deciphering the mechanism underlying late-onset Alzheimer disease Nat Rev Neurol 9 2013 25 34
56. E. Masliah, and L. Crews Genetically engineered mouse models of neurodegenerative disorders V.N. Uversky, Protein misfolding, aggregation and conformational diseases 2006 Kluwer Academic/Plenum New York
57. S.S. Sisodia, and D.L. Price Role of the beta-amyloid protein in Alzheimer's disease FASEB J 9 1995 366 370
58. D. Selkoe Amyloid b protein precursor and the pathogenesis of Alzheimer's disease Cell 58 1989 611 612 (Pubitemid 19210954)
59. D. Selkoe Amyloid β-protein deposition as a seminal pathogenic event in AD: an hypothesis Neurobiol Aging 11 1990 299
60. D. Selkoe Physiological production of the β-amyloid protein and the mechanisms of Alzheimer's disease Trends Neurosci 16 1993 403 409 (Pubitemid 23283401)
61. T. Wyss-Coray, C. Lin, F. Yan, G.Q. Yu, M. Rohde, and L. McConlogue et al. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice Nat Med 7 2001 612 618 (Pubitemid 32448330)
62. R.A. Nixon Autophagy, amyloidogenesis and Alzheimer disease J Cell Sci 120 2007 4081 4091
63. W.L. Klein ADDLs and protofibrils - the missing links Neurobiol Aging 23 2002 231 235
64. W.L. Klein, G.A. Krafft, and C.E. Finch Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum Trends Neurosci 24 2001 219 224 (Pubitemid 32204378)
65. D.M. Walsh, and D.J. Selkoe Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration Protein Pept Lett 11 2004 213 228 (Pubitemid 38689025)
66. C.C. Glabe Amyloid accumulation and pathogenesis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta Subcell Biochem 38 2005 167 177
67. C.G. Glabe Structural classification of toxic amyloid oligomers J Biol Chem 283 2008 29639 29643
68. M.P. Lambert, A.K. Barlow, B.A. Chromy, C. Edwards, R. Freed, and M. Liosatos et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins Proc Natl Acad Sci USA 95 1998 6448 6453
69. D.J. Selkoe Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior Behav Brain Res 192 2008 106 113
70. B. Caughey, and P.T. Lansbury Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders Annu Rev Neurosci 26 2003 267 298 (Pubitemid 37064935)
71. D.B. Teplow Structural and kinetic features of amyloid beta-protein fibrillogenesis Amyloid 5 1998 121 142 (Pubitemid 128691229)
72. R. Roychaudhuri, M. Yang, M.M. Hoshi, and D.B. Teplow Amyloid beta-protein assembly and Alzheimer disease J Biol Chem 284 2009 4749 4753
73. W.L. Klein Synaptotoxic amyloid-beta oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? J Alzheimers Dis 33 Suppl. 1 2013 S49 S65
74. L. Mucke, and D.J. Selkoe Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction Cold Spring Harb Perspect Med 2 2012 a006338
75. I.F. Tsigelny, Y. Sharikov, V.L. Kouznetsova, J.P. Greenberg, W. Wrasidlo, and T. Gonzalez et al. Structural diversity of Alzheimer's disease amyloid-beta dimers and their role in oligomerization and fibril formation J Alzheimers Dis 2013 10.3233/JAD-131589
76. I. Benilova, E. Karran, and B. De Strooper The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes Nat Neurosci 15 2012 349 357
77. S. Lesne, M.T. Koh, L. Kotilinek, R. Kayed, C.G. Glabe, and A. Yang et al. A specific amyloid-beta protein assembly in the brain impairs memory Nature 440 2006 352 357
78. M. Townsend, G.M. Shankar, T. Mehta, D.M. Walsh, and D.J. Selkoe Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers J Physiol 572 2006 477 492
79. T.L. Kerrigan, and A.D. Randall A new player in the synaptopathy of Alzheimer's disease - arc/arg 3.1 Front Neurol 4 2013 9
80. I. Klyubin, V. Betts, A.T. Welzel, K. Blennow, H. Zetterberg, and A. Wallin et al. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization J Neurosci 28 2008 4231 4237
81. P.N. Lacor, M.C. Buniel, P.W. Furlow, A.S. Clemente, P.T. Velasco, and M. Wood et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease J Neurosci 27 2007 796 807 (Pubitemid 46174498)
82. K.H. Gylys, J.A. Fein, F. Yang, D.J. Wiley, C.A. Miller, and G.M. Cole Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence Am J Pathol 165 2004 1809 1817 (Pubitemid 39435178)
83. A.M. Simon, L. Schiapparelli, P. Salazar-Colocho, M. Cuadrado-Tejedor, L. Escribano, and R. Lopez de Maturana et al. Overexpression of wild-type human APP in mice causes cognitive deficits and pathological features unrelated to Abeta levels Neurobiol Dis 33 2009 369 378
84. R.M. Koffie, M. Meyer-Luehmann, T. Hashimoto, K.W. Adams, M.L. Mielke, and M. Garcia-Alloza et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques Proc Natl Acad Sci USA 106 2009 4012 4017
85. R. Sultana, W.A. Banks, and D.A. Butterfield Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer's disease J Neurosci Res 88 2010 469 477
86. C.G. Almeida, D. Tampellini, R.H. Takahashi, P. Greengard, M.T. Lin, and E.M. Snyder et al. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses Neurobiol Dis 20 2005 187 198 (Pubitemid 41476246)
87. N.D. Prins, and P. Scheltens Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future Alzheimers Res Ther 5 2013 56
88. C.A. Lemere, and E. Masliah Can Alzheimer disease be prevented by amyloid-beta immunotherapy Nat Rev Neurol 6 2010 108 119
89. S.I. Mota, I.L. Ferreira, and A.C. Rego Dysfunctional synapse in Alzheimer's disease - a focus on NMDA receptors Neuropharmacology 76 Pt A 2014 16 26
90. H. Hsieh, J. Boehm, C. Sato, T. Iwatsubo, T. Tomita, and S. Sisodia et al. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss Neuron 52 2006 831 843 (Pubitemid 44828454)
91. J.J. Palop, J. Chin, and L. Mucke A network dysfunction perspective on neurodegenerative diseases Nature 443 2006 768 773 (Pubitemid 44622680)
92. J.J. Palop, L. Mucke, and E.D. Roberson Quantifying biomarkers of cognitive dysfunction and neuronal network hyperexcitability in mouse models of Alzheimer's disease: depletion of calcium-dependent proteins and inhibitory hippocampal remodeling Methods Mol Biol 670 2011 245 262
93. M. Renner, P.N. Lacor, P.T. Velasco, J. Xu, A. Contractor, and W.L. Klein et al. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5 Neuron 66 2010 739 754
94. M. Cisse, B. Halabisky, J. Harris, N. Devidze, D.B. Dubal, and B. Sun et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model Nature 469 2011 47 52
95. J. Lauren, D.A. Gimbel, H.B. Nygaard, J.W. Gilbert, and S.M. Strittmatter Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers Nature 457 2009 1128 1132
96. J. Chin, J.J. Palop, J. Puolivali, C. Massaro, N. Bien-Ly, and H. Gerstein et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease J Neurosci 25 2005 9694 9703 (Pubitemid 41510910)
97. J. Chin, J.J. Palop, G.Q. Yu, N. Kojima, E. Masliah, and L. Mucke Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice J Neurosci 24 2004 4692 4697 (Pubitemid 38656624)
98. J.W. Um, and S.M. Strittmatter Amyloid-beta induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease Prion 7 2013 37 41
99. J.W. Um, A.C. Kaufman, M. Kostylev, J.K. Heiss, M. Stagi, and H. Takahashi et al. Metabotropic glutamate receptor 5 is a co-receptor for Alzheimer abeta oligomer bound to cellular prion protein Neuron 79 2013 887 902
100. A.C. Paula-Lima, J. Brito-Moreira, and S.T. Ferreira Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease J Neurochem 126 2013 191 202
101. S. Sivanesan, A. Tan, and J. Rajadas Pathogenesis of Abeta oligomers in synaptic failure Curr Alzheimer Res 10 2013 316 323
102. M. Talantova, S. Sanz-Blasco, X. Zhang, P. Xia, M.W. Akhtar, and S. Okamoto et al. Abeta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss Proc Natl Acad Sci USA 110 2013 E2518 E2527
103. T. Kim, G.S. Vidal, M. Djurisic, C.M. William, M.E. Birnbaum, and K.C. Garcia et al. Human LilrB2 is a beta-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model Science 341 2013 1399 1404
104. A.M. Pooler, W. Noble, and D.P. Hanger A role for tau at the synapse in Alzheimer's disease pathogenesis Neuropharmacology 76 Pt A 2014 1 8
105. L.M. Ittner, Y.D. Ke, F. Delerue, M. Bi, A. Gladbach, and J. van Eersel et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models Cell 142 2010 387 397
106. K.A. Vossel, K. Zhang, J. Brodbeck, A.C. Daub, P. Sharma, and S. Finkbeiner et al. Tau reduction prevents Abeta-induced defects in axonal transport Science 330 2010 198
107. K. Shahpasand, I. Uemura, T. Saito, T. Asano, K. Hata, and K. Shibata et al. Regulation of mitochondrial transport and inter-microtubule spacing by tau phosphorylation at the sites hyperphosphorylated in Alzheimer's disease J Neurosci 32 2012 2430 2441
108. A.A. Asuni, A. Boutajangout, D. Quartermain, and E.M. Sigurdsson Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements J Neurosci 27 2007 9115 9129 (Pubitemid 47312068)
109. H. Zempel, E. Thies, E. Mandelkow, and E.M. Mandelkow Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines J Neurosci 30 2010 11938 11950
110. H. Zempel, J. Luedtke, Y. Kumar, J. Biernat, H. Dawson, and E. Mandelkow et al. Amyloid-beta oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin EMBO J 32 2013 2920 2937
111. N. Nakanishi, S.D. Ryan, X. Zhang, A. Khan, T. Holland, and E.G. Cho et al. Synaptic protein alpha1-takusan mitigates amyloid-beta-induced synaptic loss via interaction with tau and postsynaptic density-95 at postsynaptic sites J Neurosci 33 2013 14170 14183
112. M. Manczak, and P.H. Reddy Abnormal interaction of oligomeric amyloid-beta with phosphorylated tau: implications to synaptic dysfunction and neuronal damage J Alzheimers Dis 36 2013 285 295
113. M. Citron Alzheimer's disease: strategies for disease modification Nat Rev Drug Discov 9 2010 387 398
114. R. Nistico, M. Pignatelli, S. Piccinin, N.B. Mercuri, and G. Collingridge Targeting synaptic dysfunction in Alzheimer's disease therapy Mol Neurobiol 46 2012 572 587
115. S. Salomone, F. Caraci, G.M. Leggio, J. Fedotova, and F. Drago New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs Br J Clin Pharmacol 73 2012 504 517
116. K. Yang, J. Belrose, C.H. Trepanier, G. Lei, M.F. Jackson, and MacDonald J.F. Fyn a potential target for Alzheimer's disease J Alzheimers Dis 27 2011 243 252
117. A. Iwai, E. Masliah, M. Yoshimoto, N. Ge, L. Flanagan, and H.A. de Silva et al. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system Neuron 14 1995 467 475
118. R. Jakes, M.G. Spillantini, and M. Goedert Identification of two distinct synucleins from human brain FEBS Lett 345 1994 27 32 (Pubitemid 24154659)
119. G.S. Withers, J.M. George, G.A. Banker, and D.F. Clayton Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons Brain Res Dev Brain Res 99 1997 87 94 (Pubitemid 27112848)
120. P.J. Kahle, M. Neumann, L. Ozmen, V. Muller, H. Jacobsen, and A. Schindzielorz et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain J Neurosci 20 2000 6365 6373
121. S.J. Lee, H. Jeon, and K.V. Kandror Alpha-synuclein is localized in a subpopulation of rat brain synaptic vesicles Acta Neurobiol Exp 68 2008 509 515
122. L. Zhang, C. Zhang, Y. Zhu, Q. Cai, P. Chan, and K. Ueda et al. Semi-quantitative analysis of alpha-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a C-terminal specific monoclonal antibody Brain Res 1244 2008 40 52
123. D.A. Scott, I. Tabarean, Y. Tang, A. Cartier, E. Masliah, and S. Roy A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration J Neurosci 30 2010 8083 8095
124. J. Burre, M. Sharma, T. Tsetsenis, V. Buchman, M.R. Etherton, and T.C. Sudhof Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro Science 329 2010 1663 1667
125. R. Kruger, W. Kuhn, T. Muller, D. Woitalla, M. Graeber, and S. Kosel et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease Nat Genet 18 1998 106 108
126. M. Polymeropoulos, C. Lavedan, E. Leroy, S. Ide, A. Dehejia, and A. Dutra et al. Mutation in the a-synuclein gene identified in families with Parkinson's disease Science 276 1997 2045 2047 (Pubitemid 27443610)
127. J.J. Zarranz, J. Alegre, J.C. Gomez-Esteban, E. Lezcano, R. Ros, and I. Ampuero et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia Ann Neurol 55 2004 164 173 (Pubitemid 38166992)
128. M.C. Chartier-Harlin, J. Kachergus, C. Roumier, V. Mouroux, X. Douay, and S. Lincoln et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease Lancet 364 2004 1167 1169 (Pubitemid 39296604)
129. J. Simon-Sanchez, C. Schulte, J.M. Bras, M. Sharma, J.R. Gibbs, and D. Berg et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease Nat Genet 41 2009 1308 1312
130. K.A. Conway, J.D. Harper, and P.T. Lansbury Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease Nat Med 4 1998 1318 1320 (Pubitemid 28512115)
131. I.F. Tsigelny, Y. Sharikov, M.A. Miller, and E. Masliah Mechanism of alpha-synuclein oligomerization and membrane interaction: theoretical approach to unstructured proteins studies Nanomedicine 4 2008 350 357
132. A. Oueslati, M. Fournier, and H.A. Lashuel Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies Prog Brain Res 183 2010 115 145
133. G. Taschenberger, M. Garrido, Y. Tereshchenko, M. Bahr, M. Zweckstetter, and S. Kugler Aggregation of alpha-synuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons Acta Neuropathol 123 2012 671 683
134. B. Winner, R. Jappelli, S.K. Maji, P.A. Desplats, L. Boyer, and S. Aigner et al. In vivo demonstration that alpha-synuclein oligomers are toxic Proc Natl Acad Sci USA 108 2011 4194 4199
135. H.A. Lashuel, C.R. Overk, A. Oueslati, and E. Masliah The many faces of alpha-synuclein: from structure and toxicity to therapeutic target Nat Rev Neurosci 14 2013 38 48
136. V.M. Lee, and J.Q. Trojanowski Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery Neuron 52 2006 33 38 (Pubitemid 44479831)
137. K. Kosaka Diffuse Lewy body disease in Japan J Neurol 237 1990 197 204 (Pubitemid 20209309)
138. D.W. Dickson, H. Crystal, L.A. Mattiace, Y. Kress, A. Schwagerl, and H. Ksiezak-Reding et al. Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques Acta Neuropathol 78 1989 572 584 (Pubitemid 19251311)
139. P.J. Kahle, M. Neumann, L. Ozmen, V. Muller, S. Odoy, and N. Okamoto et al. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model Am J Pathol 159 2001 2215 2225 (Pubitemid 33104275)
140. M. Baba, S. Nakajo, P.H. Tu, T. Tomita, K. Nakaya, and V.M. Lee et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies Am J Pathol 152 1998 879 884 (Pubitemid 28173348)
141. M.K. Lee, W. Stirling, Y. Xu, X. Xu, D. Qui, and A.S. Mandir et al. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice Proc Natl Acad Sci USA 99 2002 8968 8973 (Pubitemid 34693667)
142. I. Horvath, C.F. Weise, E.K. Andersson, E. Chorell, M. Sellstedt, and C. Bengtsson et al. Mechanisms of protein oligomerization: inhibitor of functional amyloids templates alpha-synuclein fibrillation J Am Chem Soc 134 2012 3439 3444
143. N. Cremades, S.I. Cohen, E. Deas, A.Y. Abramov, A.Y. Chen, and A. Orte et al. Direct observation of the interconversion of normal and toxic forms of alpha-synuclein Cell 149 2012 1048 1059
144. K.M. Danzer, D. Haasen, A.R. Karow, S. Moussaud, M. Habeck, and A. Giese et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding J Neurosci 27 2007 9220 9232 (Pubitemid 47312071)
145. W. Wang, I. Perovic, J. Chittuluru, A. Kaganovich, L.T. Nguyen, and J. Liao et al. A soluble alpha-synuclein construct forms a dynamic tetramer Proc Natl Acad Sci USA 108 2011 17797 17802
146. T. Bartels, J.G. Choi, and D.J. Selkoe alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation Nature 477 2011 107 110
147. B. Fauvet, M.K. Mbefo, M.B. Fares, C. Desobry, S. Michael, and M.T. Ardah et al. Alpha-synuclein in the central nervous system and from erythrocytes, mammalian cells and E. coli exists predominantly as a disordered monomer J Biol Chem 287 2012 15345 15364
148. T. Gurry, O. Ullman, C.K. Fisher, I. Perovic, T. Pochapsky, and C.M. Stultz The dynamic structure of alpha-synuclein multimers J Am Chem Soc 135 2013 3865 3872
149. C.L. Kragh, K. Ubhi, T. Wyss-Corey, and E. Masliah Autophagy in dementias Brain Pathol 22 2012 99 109
150. D.M. Maraganore, M. de Andrade, A. Elbaz, M.J. Farrer, J.P. Ioannidis, and R. Kruger et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease J Am Med Assoc 296 2006 661 670 (Pubitemid 44200637)
151. A. Iwata, M. Maruyama, T. Akagi, T. Hashikawa, I. Kanazawa, and S. Tsuji et al. Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies Hum Mol Genet 12 2003 2625 2635 (Pubitemid 37304685)
152. J. Klucken, Y. Shin, E. Masliah, B.T. Hyman, and McLean P.J. Hsp70 Reduces alpha-synuclein aggregation and toxicity J Biol Chem 279 2004 25497 25502
153. K.S. McNaught, C. Mytilineou, R. Jnobaptiste, J. Yabut, P. Shashidharan, and P. Jennert et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures J Neurochem 81 2002 301 306 (Pubitemid 34809355)
154. K.S. McNaught, L.M. Bjorklund, R. Belizaire, O. Isacson, P. Jenner, and C.W. Olanow Proteasome inhibition causes nigral degeneration with inclusion bodies in rats Neuroreport 13 2002 1437 1441
155. J.L. Webb, B. Ravikumar, J. Atkins, J.N. Skepper, and D.C. Rubinsztein Alpha-synuclein is degraded by both autophagy and the proteasome J Biol Chem 278 2003 25009 25013 (Pubitemid 37548663)
156. A.M. Cuervo, L. Stefanis, R. Fredenburg, P.T. Lansbury, and D. Sulzer Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy Science 305 2004 1292 1295 (Pubitemid 39129234)
157. P. Desplats, H.J. Lee, E.J. Bae, C. Patrick, E. Rockenstein, and L. Crews et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein Proc Natl Acad Sci USA 106 2009 13010 13015
158. B. Spencer, R. Potkar, M. Trejo, E. Rockenstein, C. Patrick, and R. Gindi et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases J Neurosci 29 2009 13578 13588
159. L. Crews, B. Spencer, P. Desplats, C. Patrick, A. Paulino, and E. Rockenstein et al. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy PLoS ONE 5 2010 e9313
160. W.J. Schulz-Schaeffer The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia Acta Neuropathol 120 2010 131 143
161. M.L. Kramer, and W.J. Schulz-Schaeffer Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies J Neurosci 27 2007 1405 1410
162. E. Masliah, M. Mallory, R. DeTeresa, M. Alford, and L. Hansen Differing patterns of aberrant neuronal sprouting in Alzheimer's disease with and without Lewy bodies Brain Res 617 1993 258 266 (Pubitemid 23209792)
163. L.J. Hsu, Y. Sagara, A. Arroyo, E. Rockenstein, A. Sisk, and M. Mallory et al. alpha-synuclein promotes mitochondrial deficit and oxidative stress Am J Pathol 157 2000 401 410 (Pubitemid 30627559)
164. C. Manzoni, and P.A. Lewis Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies FASEB J 27 2013 3424 3429
165. M.A. Alim, Q.L. Ma, K. Takeda, T. Aizawa, M. Matsubara, and M. Nakamura et al. Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein J Alzheimers Dis 6 2004 435 442 [discussion 43-49] (Pubitemid 39287257)
166. D.L. Price, E. Rockenstein, K. Ubhi, V. Phung, N. MacLean-Lewis, and D. Askay et al. Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy - implications for excitotoxicity PLoS ONE 5 2010 e14020
167. T. Kaul, J. Credle, T. Haggerty, A.W. Oaks, E. Masliah, and A. Sidhu Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease BMC Neurosci 12 2011 79
168. T. Haggerty, J. Credle, O. Rodriguez, J. Wills, A.W. Oaks, and E. Masliah et al. Hyperphosphorylated Tau in an alpha-synuclein-overexpressing transgenic model of Parkinson's disease Eur J Neurosci 33 2011 1598 1610
169. J. Wills, J. Jones, T. Haggerty, V. Duka, J.N. Joyce, and A. Sidhu Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia Exp Neurol 225 2010 210 218
170. V. Duka, J.H. Lee, J. Credle, J. Wills, A. Oaks, and C. Smolinsky et al. Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases PLoS ONE 8 2013 e75025
171. M. Morris, A. Koyama, E. Masliah, and L. Mucke Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease PLoS ONE 6 2011 e29257
172. A. Jang, H.J. Lee, J.E. Suk, J.W. Jung, K.P. Kim, and S.J. Lee Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions J Neurochem 113 2010 1263 1274
173. K.M. Danzer, W.P. Ruf, P. Putcha, D. Joyner, T. Hashimoto, and C. Glabe et al. Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity FASEB J 25 2011 326 336
174. L. Alvarez-Erviti, Y. Couch, J. Richardson, J.M. Cooper, and M.J. Wood Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line Neurosci Res 69 2011 337 342
175. H.J. Lee, E.D. Cho, K.W. Lee, J.H. Kim, S.G. Cho, and S.J. Lee Autophagic failure promotes the exocytosis and intercellular transfer of alpha-synuclein Exp Mol Med 45 2013 e22
176. H.J. Lee, J.E. Suk, C. Patrick, E.J. Bae, J.H. Cho, and S. Rho et al. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies J Biol Chem 285 2010 9262 9272
177. L.A. Volpicelli-Daley, K.C. Luk, T.P. Patel, S.A. Tanik, D.M. Riddle, and A. Stieber et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death Neuron 72 2011 57 71
178. C. Kim, D.H. Ho, J.E. Suk, S. You, S. Michael, and J. Kang et al. Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia Nat Commun 4 2013 1562
179. L. Crews, H. Mizuno, P. Desplats, E. Rockenstein, A. Adame, and C. Patrick et al. Alpha-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice J Neurosci 28 2008 4250 4260
180. C. Hansen, E. Angot, A.L. Bergstrom, J.A. Steiner, L. Pieri, and G. Paul et al. alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells J Clin Invest 121 2011 715 725
181. K. Wakabayashi, S. Hayashi, A. Kakita, M. Yamada, Y. Toyoshima, and M. Yoshimoto et al. Accumulation of α-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy Acta Neuropathol 96 1998 445 452 (Pubitemid 28474751)
182. H. Braak, K. Del Tredici, U. Rub, R.A. de Vos, E.N. Jansen Steur, and E. Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol Aging 24 2003 197 211 (Pubitemid 36007810)
183. K.C. Luk, V. Kehm, J. Carroll, B. Zhang, P. O'Brien, and J.Q. Trojanowski et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice Science 338 2012 949 953
184. J. Hardy, and T. Revesz The spread of neurodegenerative disease N Engl J Med 366 2012 2126 2128